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Abstract: The present work describes the synthesis of the tetrapeptide H-Ala-Ala-Pro-Val-NH2 
(AAPV), an important inhibitor of the enzyme human neutrophil elastase, labelled at the C-terminus 
with a 7-methoxycoumarinyl moiety. Photophysical studies were made with spectroscopic 
characterization by UV-vis and fluorescence spectroscopy in different organic solvents and mixtures 
with aqueous HEPES solution, in order to simulate physiological conditions.  
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Introduction 
 
Coumarins (the trivial designation of 3-oxo-3H-benzopyrans) are an important family of compounds 
that have been reported as fluorescent labels and probes [1]. Coumarins are well known fluorophores 
with an extended spectral range, high fluorescence quantum yields, good photostability and solubility 
in common solvents [1-3]. As most amino acids are poor UV-absorbing, fluorescence labelling is often 
employed in peptides and, for example, a peptide or protein bound to a fluorescent moiety may be an 
important tool for conformational studies of protein-protein and ligand-receptor interactions. 
Coumarins have also been applied in the synthesis of photolabile protecting groups to release 
relevant biomolecules by UV and visible light irradiation [4,5] and can thus be used in the preparation 
of photoactive prodrugs.  
The tetrapeptide H-Ala-Ala-Pro-Val-NH2 (AAPV) is an important inhibitor of the enzyme human 
neutrophil elastase, HNE), which is present in high levels in a variety of inflammatory disorders, such 
as psoriasis. The inhibition of HNE by this hydrophobic sequence occurs when the peptide fits the P-
P1 subsites of elastase and competitively inhibits HNE [6,7]. Some studies have been conducted for 
the use of this peptide as a therapeutic agent for transdermal delivery [6]. Therefore, in the present 
communication the tetrapeptide AAPV was synthesized by the stepwise coupling of the corresponding 
amino acids in solution and labelled at the C-terminus with a 7-methoxycoumarinyl moiety. This 
peptide conjugate was submitted to photophysical studies for its spectroscopic characterization by 
UV-vis and fluorescence spectroscopy in different organic solvents and mixtures with aqueous 
HEPES solution, in order to simulate physiological conditions.  
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Experimental 
 
1. Synthesis of 4-chloromethyl-7-methoxycoumarin 
3-Methoxyphenol (0.25 g, 2.0 x 10
-3
 mol) was mixed with ethyl 4-chloro-3-oxobutanoate (1.5 eq, 0.42 
mL, 3.0 x 10
-3
 mol) at room temperature and aqueous sulphuric acid 70% (5 mL) was added. The 
reaction mixture was stirred at room temperature for 24 hours. The mixture was poured into ice, the 
formed precipitate was filtered, washed with water and dried in the oven at 50 ºC. The resulting solid 
was purified by recrystallization using methanol/diethyl ether. The pure compound was obtained as a 
greyish solid (0.195 g, 43%). 
1
H NMR (400 MHz, CDCl3): δ = 3.89 (3H, s, OCH3), 4.63 (2H, d, J 0.8 
Hz, CH2), 6.41 (1H, s, H-3), 6.86 (1H, d, J 2.4 Hz, H-8), 6.91 (1H, dd, J 8.8 and 2.4 Hz , H-6), 7.56 
(1H, d, J 8.8 Hz, H-5).  
 
2. Synthesis of the peptide AAPV labeled with coumarin 
2.1 Coupling of coumarin to the C-terminal amino acid and deprotection 
4-Chloromethyl-7-methoxycoumarin (0.1557 g, 6.90 x 10
-4 
mol) was dissolved in dry 
dimehtylformamide (2 mL), potassium fluoride (0.1203 g, 2.1 x 10
-3 
mol, 3 eq) and the C-terminal 
protected amino acid N-tert-butyloxycarbonyl-L-valine (Boc-Val-OH) (0.150 g, 6.90 x 10
-4
 mol, 1 eq) 
were added. The reaction mixture was stirred at room temperature for 4 days. Potassium fluoride was 
filtered and the solvent was removed by rotary evaporation. The residue obtained was an orange solid 
(0.246 g, 87%). 
1
H NMR (400 MHz, CDCl3): δ = 0.89 (3H, d, J 6.8 Hz, CH3 Val), 0.97 (3H, d, J 6.8 Hz, 
CH3 Val), 1.43 (9H, s, Boc), 2.12-2.17 (1H, m, β-CH Val), 3.86 (3H, s, OCH3), 5.05 (1H, d, J 8.4 Hz, α-
CH Val), 5.24-5.33 (2H, m, CH2), 6.33 (1H, d, J 1.2 Hz, H-3), 6.82-6.86 (2H, m, H-6 and H-8), 7.40 
(1H, d, J 8.8 Hz, H-5), 8.88 (1H, s, NH).  
The N-protecting group of the obtained valine-coumarin conjugate (0.246 g, 6.08 x 10
-4 
mol) was 
cleaved with trifluoroacetic acid (2.05 mL, 6.08 x 10
-4
 mol) in dichloromethane (4 mL) at room 
temperature for 1 hour. The solvents were evaporated and the residue was treated with diethyl ether 
(5 mL) yielding a yellow solid (0.2312 g, quantitative yield). 
1
H NMR (400 MHz, CDCl3): δ = 1.19 (6H, 
m, 2 x CH3 Val), 2.51-2.54 (1H, m, β-CH Val), 3.89 (3H, s, OCH3), 5.27-5.34 (2H, m, CH2), 5.50-5-53 
(1H, m, α-CH Val), 6.66 (1H, s, H-3), 6.85 (1H, d, J 2.0 Hz, H-8), 6.90 (1H, dd, J 8.8 and 2.8 Hz, H-6), 
7.40 (1H, d, J 8.8 Hz, H-5). 
 
2.2 Coupling to Boc-Pro-OH and deprotection of the dipeptide 
N-tert-butyloxycarbonyl-L-proline (Boc-Pro-OH) (0.163 g, 7.57 x 10
-4
 mol) was dissolved in acetonitrile 
(10 mL), 1-hydroxybenzotriazole (HOBt) (0.1023 g, 7.57 x 10
-4
 mol, 1 eq) was added and the reaction 
mixture was stirred at room temperature for 30 minutes. Then N,N’-dicyclohexylcarbodiimide (DCC) 
(0.1562 g, 7.57 x 10
-4
 mol, 1 eq) was added and the mixture was stirred at room temperature for 2 
hours. Separately, the previously synthesized valine-coumarin conjugate (0.2312 g, 7.57 x 10
-4
 mol) 
was dissolved in acetonitrile (5 mL) and then added to the reaction mixture containing Boc-Pro-OH 
and the mixture heated at reflux for 20 hours. The formed solid (the corresponding urea) was filtered 
and the solvent was evaporated in a rotary evaporator. The residue was dissolved in ethyl acetate (25 
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mL) and extracted with hydrochloric acid 1M (25 mL) and then with sodium hydrogencarbonate 10% 
(25 mL). Anhydrous magnesium sulphate was added to the organic layer, filtered and the solvent was 
evaporated under reduced pressure. The dipeptide-coumarin conjugate obtained was an orange oil 
(0.2417 g, 64%). 
1
H NMR (400 MHz, CDCl3): δ = 0.88-0.94 (6H, m, 2 x CH3 Val), 1.41 (9H, s, Boc), 
1.43-1.47 (2H, m, CH2 Pro), 1.87-1.90 (2H, m, CH2 Pro), 1.95-2.03 (1H, m, β-CH Val), 3.41-3.45 (2H, 
m, CH2 Pro), 3.84 (3H, s, OCH3), 4.30-4.36 (1H, m, α-CH Val), 4.47-4.53 (1H, m, α-CH Pro), 5.25-
5.31 (2H, m, CH2), 6.33 (1H, s, H-3), 6.80 (1H, s, H-8), 6.83 (1H, dd, J 8.8 and 2.0 Hz, H-6), 7.39 (1H, 
d, J 9.2 Hz, H-5). 
The N-protecting group of the obtained dipeptide-coumarin conjugate (0.2417 g, 4.81 x 10
-4 
mol) was 
cleaved with trifluoroacetic acid (1.62 mL, 4.81 x 10
-4
 mol) in dichloromethane (4 mL) at room 
temperature for 1 hour. The solvents were evaporated and the residue was treated with diethyl ether 
(5 mL) yielding a yellow solid (0.1207 g, 63
 
%). 
1
H NMR (400 MHz, CDCl3): δ = 0.97-1.00 (6H, m, 2 x 
CH3Val), 1.98-2.30 (4H, m, 2 x CH2 Pro), 2.45-2.50 (1H, m, β-CH Val), 3.45-3.50 (2H, m, CH2 Pro), 
3.88 (3H, s, OCH3), 4.47-4.50 (1H, m, α-CH Pro), 4.86-4.90 (1H, m, α-CH Val), 5.30-5.33 (2H, m, 
CH2), 6.37 (1H, s, H-3), 6.83 (1H, d, J 2.4 Hz, H-8), 6.88 (1H, dd, J 8.8 and 2.4 Hz, H-6), 7.39 (1H, d, 
J 8.8 Hz, H-5), 8.12 (1H, d, J 7.2 Hz, NH-Val). 
 
2.3 Coupling to Boc-Ala-OH and deprotection of the tripeptide 
N-tert-butyloxycarbonyl-L-alanine (Boc-Ala-OH) (0.057 g, 3.01 x 10
-4
 mol) was dissolved in acetonitrile 
(10 mL), HOBt (0.041 g, 3.01 x 10
-4
 mol, 1 eq) was added and the reaction mixture was stirred at 
room temperature for 30 minutes. Then DCC (0.062 g, 3.01 x 10
-4
 mol, 1 eq) was added and the 
mixture was stirred at room temperature for 2 hours. Separately, the previously synthesized dipeptide-
coumarin conjugate (0.1207 g, 3.01 x 10
-4
 mol) was dissolved in acetonitrile (5 mL) and added to the 
reaction mixture containing Boc-Ala-OH and heated at reflux for 20 hours.  The formed solid was 
filtered and the solvent was evaporated in a rotary evaporator. The residue was dissolved in ethyl 
acetate (25 mL) and extracted with hydrochloric acid 1M (25 mL) and then with sodium 
hydrogencarbonate 10% (25 mL). Anhydrous magnesium sulphate was added to the organic layer, 
filtered and the solvent was evaporated under reduced pressure. The crude tripeptide-coumarin 
conjugate was obtained as an orange oil (0.069 g, 40%). 
1
H NMR (400 MHz, CDCl3): δ = 0.86-0.90 
(6H, m, 2 x CH3 Val), 1.31 (9H, s, Boc), 1.39 (3H, d, J 6.0 Hz, CH3 Ala), 1.85-1.90 (2H, m, CH2 Pro), 
1.98-2.02 (2H, m, CH2 Pro), 2.05-2.11 (1H, m, β-CH Val), 3.41-3.46 (2H, m, CH2 Pro), 3.84 (3H, s, 
OCH3), 4.45-4.48 (2H, m, α-CH Val and α-CH Ala), 4.54-4.59 (1H, m, α-CH Pro), 5.22-5.29 (2H, m, 
CH2), 5.48 (1H, d, J 8.4 Hz, NH Ala), 6.37 (1H, s, H-3), 6.80-6.85 (2H, m, H-6 and H-8), 7.38 (1H, d, J 
8.4 Hz, H-5), 7.57 (1H, d, J 8.0 Hz, NH-Val). 
The N-protecting group of the obtained tripeptide-coumarin conjugate (0.115 g, 2.00 x 10
-4 
mol) was 
cleaved with trifluoroacetic acid (0.667 mL, 2.00 x 10
-4
 mol) in dichloromethane (2 mL) at room 
temperature for 1 hour. The solvents were evaporated and the residue was treated with diethyl ether 
(5 mL) yielding a yellow solid (0.0756 g, quantitative yield). 
1
H NMR (400 MHz, CDCl3): δ = 0.90-0.95 
(6H, m, 2 x CH3 Val), 1.57 (3H, d, J 6.0 Hz, CH3 Ala), 1.83-2.00 (4H, m, 2 x CH2 Pro), 2.18-2.21 (1H, 
m, β-CH Val), 3.46-3.50 (2H, m, CH2 Pro), 3.88 (3H, s, OCH3), 4.31-4.33 (1H, m, α-CH Val), 4.51-4.54 
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(1H, m, α-CH Pro), 4.70-4.74 (1H, s, α-CH Ala), 5.26-5.35 (2H, m, CH2), 6.45 (1H, s, H-3), 6.82-6.89 
(2H, m, H-6 and H-8), 7.40 (1H, d, J 8.8 Hz, H-5), 7.59 (1H, d, J 8.4 Hz, NH-Val). 
  
2.4 Coupling to Boc-Ala-OH and isolation of the tetrapeptide 
Boc-Ala-OH (0.028 g, 1.46 x 10
-4
 mol) was dissolved in acetonitrile (10 mL), HOBt (0.020 g, 1.46 x 10
-
4
 mol, 1 eq) was added and the reaction mixture was stirred at room temperature for 30 minutes. Then 
DCC (0.030 g, 1.46 x 10
-4
 mol, 1 eq) was added and the mixture was stirred at room temperature for 2 
hours. Separately, the previously synthesized tripeptide-coumarin conjugate (0.0756 g, 1.46 x 10
-4
 
mol) was dissolved in acetonitrile (5 mL) and then added the reaction mixture containing Boc-Ala-OH 
and heated at reflux for 20 hours.  The formed solid was filtered and the solvent was evaporated in a 
rotary evaporator. The residue was dissolved in ethyl acetate (25 mL) and extracted with hydrochloric 
acid 1M (25 mL) and then with sodium hydrogencarbonate 10% (25 mL). Anhydrous magnesium 
sulphate was added to the organic layer, filtered and the solvent was evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography using 
dichloromethane/methanol (50:1) as eluent, the fractions containing the product were combined and 
evaporated, and the desired tetrapeptide-coumarin conjugate was obtained as a yellow oil (0.0165 g, 
18 %). 
1
H NMR (400 MHz, CDCl3): δ= 0.90-0.94 (6H, m, 2 x CH3 Val), 1.34-1.39 (6H, m, 2 x CH3 Ala), 
1.44 (9H, s, Boc), 1.75-1.90 (2H, m, CH2 Pro), 1.98-2.05 (1H, m, CH2 Pro), 2.15-2.21 (1H, m, β-CH 
Val), 2.40-2.45 (1H, m, CH2 Pro), 3.51-3.66 (2H, m, CH2 Pro), 3.89 (3H, s, OCH3), 4.28 (1H, br s, α-
CH Ala), 4.56-4.59 (1H, m, α-CH Val), 4.69-4.72 (2H, m, α-CH Pro), 4.77-4.81 (1H, m, α-CH Ala), 
5.19 (1H, br s, NH Ala), 5.30-5.36 (2H, m, CH2), 6.58 (1H, s, H-3), 6.86-6.90 (2H, m, H-6 and H-8), 
7.41 (1H, d, J 8.4 Hz, H-5), 7.67 (1H, d, J 8.0 Hz, NH-Val). 
13
C NMR (100.6 MHz, CDCl3): δ= 17.71 
(CH3 Ala), 18.58 (CH3 Ala), 18.89 (CH3 Val), 19.09 (CH3 Val), 25.14 (CH2 Pro), 26.58 (CH2 Pro), 28.32 
(C(CH3)3), 31.18 (β-CH Val), 46.65 (α-CH Ala), 47.40 (CH2 Pro), 50.06 (α-CH Ala), 55.82 (OCH3), 
57.74 (α-CH Pro), 59.84  (α-CH Val), 61.86 (CH2), 79.90 (C(CH3)3), 101.29 (C-8), 110.34 (C-3), 
110.48 (C-4a), 112.74 (C-6), 124.37 (C-5), 148.53 (C-4), 154.86 (C8a), 155.53 (C=O Boc), 161.04 (C-
2), 162.95 (C-7), 170.56 (C=O Pro), 170.81 (C=O Val), 172.26 (C=O Ala), 172.94 (C=O Ala).  
 
 
Results and Discussion 
 
4-Chloromethyl-7-methoxycoumarin was obtained by a Pechmann reaction between 3-
methoxyphenol and ethyl 4-chloro-3-oxobutanoate, catalised by acid, in 43% yield (Scheme 1), by a 
previously published procedure [8]. 
 
Scheme 1. Synthesis of 4-chloromethyl-7-methoxycoumarin by a Pechmann reaction. 
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This compound bearing a reactive chloromethyl group was used in the derivatization of the carboxylic 
acid function C-terminal amino acid (valine) of the desired peptide in the presence of potassium 
fluoride. The protected ester conjugate was obtained in excellent yield (87%) and then the N-
protecting tert-butyloxycarbonyl (Boc) group was removed by acidolysis with trifluoracetic acid, 
resulting in the deprotected valine-coumarin conjugate (Scheme 2). 
 
Scheme 2. Synthesis of the valine-coumarin ester conjugate. 
 
The coupling of the remaining amino acids was carried out with a standard DCC/HOBt coupling 
procedure, followed by the removal of the N-protecting group after each coupling step (Scheme 3). 
The coumarin-labelled therapeutic tetrapeptide was obtained in the form of oil in 18% yield and 
charaterised by 
1
H and 
13
C NMR. 
 
Coumarin derivatives are known fluorophores and the photophysical study of this tetrapetide-
coumarin conjugate was made by UV-Vis and fluorescence spectroscopy in different organic solvents 
and mixtures with aqueous HEPES solution, in order to simulate physiological conditions. The 
solvents were chosen for being miscible with water (with protic and aprotic character) and the organic 
solvent-aqueous HEPES mixture is important for carrying out future work on the photocontrolled 
release of the tetrapeptide by irradiation of the fluorescent conjugate. 
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Scheme 3. Synthesis of tetrapeptide-coumarin conjugate by DCC/HOBt coupling.  
 
 
The absorption and fluorescence spectra of degassed 10
-5
 M solutions were measured and the data 
collected (absorption and emission maxima, molar absorptivities and fluorescence quantum yields) is 
presented in the Table 1. The relative fluorescence quantum yields were calculated using 9,10-
diphenylanthracene as standard (ΦF = 0.95 in ethanol) [9]. For the determination of the quantum 
yields, the absorbance of the solutions did not exceed 0.1 and excitation was made at the wavelength 
of maximum absorption.  
 
Table 1 - UV-visible absorption and emission data for the tetrapeptide-coumarin conjugate in different 
organic solvents and mixtures with aqueous solutions. 
 
Solvent 
UV-Vis Fluorescence  
λmax (nm) log ε λem (nm) ΦF 
Stokes’ 
shift (nm) 
EtOH 325 4.05 394 0.34 69 
 MeOH 319 4.11 399 0.58 80 
ACN 319 4.24 393 0.12 74 
MeOH/HEPES (80:20) 325 4.29 400 0.76 75 
ACN/HEPES (80:20) 320 3.54 397 0.56 77 
 
By comparison of the absorption and emission maxima in the different solvents, no significant 
differences were observed, with values in the range 319-325 nm and 393-400 nm, respectively. The 
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Stokes’ shift (λ) was between 69 and 80 nm, which is an advantageous property in fluorescence 
techniques, as it will minimize self-quenching phenomena.  
Considering the relative fluorescence quantum yields, it was found that the tetrapetide-coumarin 
conjugate was more emissive in the aqueous solvent mixture by comparison of the ΦF in the organic 
solvent (MeOH or ACN) and in the corresponding organic solvent-aqueous HEPES buffer mixture. 
Overall, the fluorescence quantum yield was higher in MeOH or MeOH/HEPES (80:20). In Figure 1, 
the fluorescence spectra of the tetrapetide-coumarin conjugate in the various solvents (ca. 7.5 x 10
-6
 
M) are shown.  
 
Figure 1. Emission spectra of tetrapetide-coumarin conjugate in various solvents (C= 7.5 x 10
-6
 M). 
 
 
Conclusions 
 
A fluorescently labelled tetrapeptide bearing a 7-methoxycoumarinyl moiety was obtained by 
sequential coupling. The sequence Ala-Ala-Pro-Val is of interest due to its potential as therapeutic 
agent for transdermal delivery for the inhibition of skin inflammatory processes. The labelling of such 
peptide with a fluorophore at the C-terminal will enable its application in fluorescence-based activity 
studies and in the photorelease of the active peptide from a photoactive prodrug. The photophysical 
study in different solvents revealed that the 7-methoxycoumarinyl moiety is an appropriate fluorogenic 
reagent for the derivatisation of this peptide due to the high Stokes’ shifts and good to excellent 
fluorescent quantum yields obtained. 
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